Please assess the completion status of the following clinical trial:

Trial Title: Using Intranasal Midazolam (INM) and Lidocaine for Uncooperative Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* uncooperative children scored 1 or 2 on Frankle Scale.~* had no medical history of neurological or cognitive alterations.~* No facial deformities.~* ASA Classification I.~* requiring dental treatment under local anesthesia.~Exclusion Criteria:~* known allergy to midazolam or any other benzodiazepines.~* upper respiratory tract infection with nasal discharge.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- A (Midazolam) (Type: ACTIVE_COMPARATOR): 21 children received 0.5 mg/kg intranasal medication (midazolam), with a maximum dose of 10 mg, via a spray of 0.2 ml per puff, administering the drug was alternated between the two nostrils of the child.
- B (Lidocaine-Midazolam) (Type: EXPERIMENTAL): 21 children received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg intranasal medication (midazolam),administering the drug was alternated between the two nostrils of the child, with a maximum dose of 10 mg via a spray of 0.2 ml per puff.
- C (Placebo) (Type: PLACEBO_COMPARATOR): 21 children received intranasal medication (saline 9% as placebo), 0.5 mg/kg, with a maximum dose of 10 mg via a spray of 0.2 ml per puff,administering the drug was alternated between the two nostrils of the child.

Based on this trial design, predict the completion outcome and termination type (if applicable).